Showing 1881-1890 of 2192 results for "".
- Hypertensive Pregnancies Linked to Increased Risk of Neurologic Conditionshttps://practicalneurology.com/news/hypertensive-pregnancies-linked-to-increased-risk-of-neurological-conditions/2470945/A Swedish register-based cohort study, published in JAMA Neurology, has found that women who experience gestational hypertension, preeclampsia, or eclampsia during pregnancy face an elevated risk of developing neurologic disorders in the months to years following childbirth, including mi
- Warning for Guillain-Barré Syndrome Added to the Labels of 2 RSV Vaccineshttps://practicalneurology.com/news/warning-for-guillain-barre-syndrome-added-to-the-labels-of-2-rsv-vaccines/2470942/The prescribing information for the vaccines Abrysvo (respiratory syncytial virus vaccine; Pfizer, New York, NY) and Arexvy (respiratory syncytial virus vaccine, adjuvanted; GSK, London, United Kingdom) has been updated to include new warnings for the risk of Guillain-Barré syndrome (GBS).
- Frailty Linked to Greater Risk of Dementiahttps://practicalneurology.com/news/frailty-linked-to-greater-risk-of-dementia/2470643/Frailty measurements may enable the identification of individuals at higher risk of dementia up to 9 years before the onset of the disorder, according to study results published in JAMA Neurology. According to the study authors, the findings demonstrate the potential utility of frailty m
- Children with Migraine Can Now Receive Neuromodulatory Treatment with the Nerivio REN Devicehttps://practicalneurology.com/news/children-with-migraine-can-now-receive-neuromodulatory-treatment-with-the-nerivio-device-1/2470639/The Food and Drug Administration (FDA) has expanded the age indication for Nerivio (Theranica, Bridgewater Township, NJ), making it the first non-drug therapy and prescribed preventive treatment for children with migraine aged ≥8 years. Nerivio is a remote electrical neuromodulation (REN) devi
- Left Atrial Appendage Occlusion Reduced Risk of Ischemic Stroke for People with Atrial Fibrillation Compared with Oral Anticoagulation Therapy Alonehttps://practicalneurology.com/news/left-atrial-appendage-occlusion-reduced-risk-of-ischemic-stroke-for-people-with-atrial-fibrillation-compared-with-oral-anticoagulation-therapy-alone/2470629/Left atrial appendage occlusion (LAAO) was superior to continued oral anticoagulation therapy (OAT) alone in reducing risk of ischemic stroke for people with nonvalvular atrial fibrillation (AF) who had a previous thrombotic event (TE) despite taking an OAT. The results of an international cohort
- Favorable Results for Radiprodil Tx for GRIN Disorders Leads to Launch of Study to Test Treatment in Those with Tuberous Sclerosis or Focal Cortical Dysplasiahttps://practicalneurology.com/news/favorable-results-for-radiprodil-tx-for-grin-disorders-leads-to-launch-of-study-to-test-treatment-in-those-with-tuberous-sclerosis-or-focal-cortical-dysplasia/2470617/Treatment with radiprodil (GRIN Therapeutics, New York, NY), a selective, potent negative allosteric modulator of the N-methyl-D-aspartate receptor subtype SB (NR2B or GluN2B), was well tolerated and associated with a significant reduction in seizure frequency in children with GRIN-related neurod
- Alzheimer's Drug Discovery Foundation Announces Development of Comprehensive Biomarker Observatoryhttps://practicalneurology.com/news/alzheimers-drug-discovery-foundation-announces-development-of-comprehensive-biomarker-observatory/2470602/The Alzheimer’s Drug Discovery Foundation (ADDF; New York, NY) announced the investment of $3.2 million to the University of Nevada Las Vegas (UNLV) to develop the first ever Biomarker Observatory for Alzheimer disease (AD). The Biomarker Observatory is designed to record and categorize inf
- FDA Greenlights First Treatment for Niemann-Pick Disease Type Chttps://practicalneurology.com/news/fda-greenlights-first-treatment-for-niemann-pick-disease-type-c/2470589/The Food and Drug Administration (FDA) has approved Miplyffa (arimoclomol; Zevra Therapeutics, Celebration, FL) for use in combination with miglustat for the treatment of neurologic manifestations of Niemann-Pick disease type C (NPC) for adult and pediatric patients aged ≥2 years. Miplyffa is
- McDonald Criteria Updates for MS Diagnosis Announcedhttps://practicalneurology.com/news/mcdonald-criteria-updates-for-ms-diagnosis-announced/2470587/Proposed revisions to the 2017 McDonald diagnostic criteria for multiple sclerosis (MS) were announced at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The updates, which will be published later this year, provide guidance on the use of im
- Long-Term Data Reveal Ocrevus Comparable to Tysabri Tx in Effectiveness, Safety Outcomeshttps://practicalneurology.com/news/long-term-data-reveals-ocrevus-comparable-to-tysabri-tx-in-effectiveness-safety-outcomes/2470583/Treatment with Ocrevus (ocrelizumab; Genentech, South San Francisco, CA) for people with multiple sclerosis (MS) showed comparable effectiveness, safety, and treatment persistence to treatment with Tysabri (natalizumab; Biogen, Cambridge, MA) over a 5-year observation period. The results of a lon